Carfilzomib, Bortezomib Combo Shows Potential for Reducing Tumor Growth in Melanoma Cells

April 15th 2021, 3:45pm


The in vitro study of melanoma cells analyzed the molecular mechanisms of the pair of proteasome inhibitors, finding that they reduced B16-F1 tumor growth.

CDC, FDA Call for Pause of J&J COVID-19 Vaccine After Safety Concerns Around Clotting

April 13th 2021, 3:18pm


After cases of rare and severe blood clots led to 1 death and 1 hospitalization, the CDC and FDA will pause the use of Johnson & Johnson's (J&J) COVID-19 vaccine.

Bortezomib Appears to Increase Fall Risk in Elderly Patients With MM, Study Suggests

April 9th 2021, 11:45am


Patients who experienced a fall within 12 months of multiple myeloma (MM) treatment initiation had a shorter median survival compared to those without falls.

Older Patients With MM Can Forgo Steroids in Treatment and See Similar Outcomes

April 4th 2021, 12:45pm


The combination of lenalidomide with steroid dexamethasone is standard of care in multiple myeloma (MM), but new research shows older patients can be spared the steroids.

FDA Approves Isatuximab, Carfilzomib, Dexamethasone Combination for RRMM

April 3rd 2021, 9:30am


Multiple myeloma is the second most common blood cancer, affecting more than 130,000 US patients.

The Impact of Sickle Cell Disease Severity on HRQOL and Economic Outcomes

April 1st 2021, 12:40pm


Disease severity was strongly associated with health-related quality of life, moderately associated with use of disability insurance, and weakly associated with household income for patients with sickle cell disease.

Trial Analyzes Efficacy of Tailoring MM Treatment to MRD Response

March 25th 2021, 1:30pm


Twice weekly high doses of carfilzomib in combination with lenalidomide and dexamethasone was tolerable and effective among patients with newly diagnosed multiple myeloma.

Many Options, Many Updates to NCCN Guidelines in Multiple Myeloma

March 24th 2021, 5:45pm


Updates to the NCCN Guidelines in multiple myeloma reflect recent trial results, giving clinicians and patients many choices.

Optimizing the Use of MRD Testing in Multiple Myeloma

March 18th 2021, 7:30pm


Minimal residual disease (MRD) is being used more frequently in clinical trials and to identify the best treatment course for patients, but unknowns remain about the optimal use of MRD testing.

Lenacapavir Against HIV Demonstrates Ongoing Potential

March 16th 2021, 5:37pm


The safety and effectiveness of the long-acting agent is backed by data from trials of the drug among treatment-experienced individuals living with HIV-1 whose viral load is on the rise due to other regimens failing. Investigation continues among these patients, as well as treatment-naive patients.